Managing chronic liver diseases requires a comprehensive assessment of the patient's nutritional status. Recent studies demonstrate that sarcopenia in autoimmune hepatitis (AIH) significantly impacts clinical outcomes and survival. This muscle-wasting condition serves as a vital prognostic indicator. Furthermore, clinical evidence suggests that muscle mass loss occurs more frequently in AIH than in other cholestatic diseases like primary biliary cholangitis (PBC).

The Prevalence of Sarcopenia in Autoimmune Hepatitis

Research comparing AIH and PBC patients shows a striking difference in muscle depletion. While both conditions involve chronic inflammation, the prevalence of a low psoas muscle mass index (PMI) is significantly higher in those with AIH. Specifically, approximately 32.8% of AIH patients exhibit sarcopenia, compared to only 17.0% in the PBC group. Consequently, clinicians must prioritize screening for muscle loss during the initial diagnostic workup.

Assessing Prognosis Using Psoas Muscle Index

CT-based assessment of the psoas muscle index provides essential data for risk stratification. In patients with AIH, a low PMI correlates strongly with poorer survival rates. Other factors that worsen the prognosis include higher MELD scores and the presence of cirrhosis. Therefore, integrating PMI measurements into routine evaluations allows for more precise patient management and earlier interventions.

FAQs on Muscle Loss in Liver Disease

What is the psoas muscle mass index (PMI)?

The PMI is a CT-derived measurement used to quantify skeletal muscle mass. It is calculated by dividing the cross-sectional area of the psoas muscle at the L3 vertebrae level by the square of the patient's height.

Why is sarcopenia in autoimmune hepatitis common?

The high prevalence of sarcopenia in AIH may stem from systemic inflammation and the severity of the underlying liver dysfunction. Additionally, the prolonged use of corticosteroids can induce muscle catabolism.

Does muscle loss affect survival in PBC?

While sarcopenia is less frequent in PBC than in AIH, studies indicate that it still serves as an independent risk factor for adverse events and mortality in patients with primary biliary cholangitis.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Tadokoro T et al. Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic Impact. Hepatol Res. 2026 May 09. doi: 10.1111/hepr.70203. PMID: 42104812.

Goenka MK, et al. Psoas Muscle Index: A Simple and Reliable Method of Sarcopenia Assessment on Computed Tomography Scan in Chronic Liver Disease and its Impact on Mortality. J Clin Exp Hepatol. 2023 Mar-Apr;13(2):220-227.

Yang F, et al. Prevalence and effect on prognosis of sarcopenia in patients with primary biliary cholangitis. Front Nutr. 2024 Feb 29;11:1347043.